綠葉製藥(02186.HK)抗精神分裂症新藥「瑞欣妥」正式在華上市
綠葉製藥(02186.HK)宣布,自主研發的抗精神分裂症新藥「瑞欣妥」(注射用利培酮微球II)正式在華上市,將為國內首個自主研發的第二代抗精神病藥長效針劑,預期每兩周肌肉注射一次,可顯著改善口服抗精神病藥物在精神分裂症患者中普遍存在的用藥依從性。
集團總裁楊榮兵表示,瑞欣妥上市,意味著綠葉製藥成功打破海外技術的長期壟斷,預期可推動旗下微球技術平台後續更多創新微球製劑產品加速上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.